Literature DB >> 930944

Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies.

C L Masters, R L Dawkins, P J Zilko, J A Simpson, R J Leedman.   

Abstract

Myasthenia gravis with thymic hyperplasia developed in a patient with Wilson's disease after eight years of penicillamine treatment. Four months prior to the onset of myasthenia, penicillin hypersensitivity was observed. Immunofluorescence on the excised thymus revealed immunoglobulin and complement deposition, but the myasthenia persisted after thymectomy and continuation of penicillamine therapy. Increased antiacetylcholine receptor antibody was demonstrable throughout. This patient subsequently became pregnant, enabling studies to be performed on the transplacental transfer of the immunoglobulin G (IgG) class antiacetylcholine receptor antibody. Eleven cases of rheumatoid arthritis with penicillamine-associated antistriational antibodies have also been observed; in three of these cases there was evidence of myasthenia gravis. These observations extend earlier reports of the association of penicillamine with myasthenia gravis and suggest that antistriational antibody, antiacetylcholine receptor antibody and thymic hyperplasia may be independent effects of penicillamine therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 930944     DOI: 10.1016/0002-9343(77)90153-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 2.  Immunological features of polymyositis/dermatomyositis.

Authors:  W M Behan; P O Behan
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.

Authors:  I A Jaffe
Journal:  Springer Semin Immunopathol       Date:  1981

4.  Anti-acetylcholine receptor antibodies.

Authors:  A Vincent; J Newsom Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 5.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

6.  Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features.

Authors:  J P Delamere; S Jobson; L P Mackintosh; L Wells; K W Walton
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

7.  Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4.

Authors:  P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

Review 8.  Ocular myasthenia gravis after D-penicillamine administration.

Authors:  L J Katz; R L Lesser; J R Merikangas; J P Silverman
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

9.  Antibodies to the acetylcholine receptor in myasthenic dogs.

Authors:  M Garlepp; B Farrow; P Kay; R L Dawkins
Journal:  Immunology       Date:  1979-08       Impact factor: 7.397

10.  HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

Authors:  M J Garlepp; R L Dawkins; F T Christiansen
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.